Ethicon, a Johnson & Johnson company, has completed the acquisition of Acclarent following clearance under the Hart-Scott-Rodino Antitrust Improvement Act. Acclarent is a medical technology company engaged in designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT).

Gary Pruden, Group chairman of Johnson & Johnson, with responsibility for Ethicon, said: “By bringing together the strengths and experiences of the two companies, we create a unique way to innovate in the surgical ENT space. The surgical ENT market is underpenetrated and there is opportunity to help more patients restore their quality of life with less-invasive surgical solutions. We look forward to working with Acclarent and its customers to do this.”

The closing of the transaction is subject to customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The boards of directors of both companies and the shareholders of Acclarent have approved the transaction.

Acclarent’s focus is on achieving the goals of sinus surgery with endoscopic, minimally-invasive devices. Through its Balloon Sinuplasty technology and other products, the company offers ENT patients alternatives to medical therapy and conventional surgical approaches.